prevention of disease relapse after chemotherapy and stem cell transplant
Hongtao Liu, MD, PhD, is a hematologist and medical oncologist, specializing in the diagnosis and treatment of leukemia, stem cell transplantation and cellular therapy. Dr. Liu is currently assistant professor of medicine at University of Chicago. He received MD and Ph.D in immunology from Beijing Medical University, he finished his hematology/oncology fellowship training at University of Chicago. In addition to his clinical role, Dr. Liu is an active researcher. He aims to develop immunotherapy to eliminate minimal residual diseases after chemotherapy or stem cell transplant to fight cancer cells and prevent disease relapse. Dr. Liu has received funding for his work from prominent organizations, including the American Cancer Society, Cancer Research Foundation, and K12 Paul Calabresi Career Development in Clinical Oncology Award. He has been the principal investigator for several investigator-initiated clinical trials focusing on immunotherapy and maintenance therapy to prevent disease relapse in acute leukemia after chemotherapy and stem cell transplantation. He is the national PI of the NCI 9706 REMAIN trial to use PD1 antibody, nivolumab, as maintenance treatment to prevent disease relapse in patients with AML. He is a member of ASH, ASCO, ASBMT and CAHON.